Connect Biopharma Holdings Limited (CNTB)

Market Cap	48.08M
Revenue (ttm)	24.12M
Net Income (ttm)	-21.38M
Shares Out	55.25M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,434
Open	0.871
Previous Close	0.860
Day's Range	0.766 - 0.909
52-Week Range	0.765 - 2.660
Beta	-0.49
Analysts	Strong Buy
Price Target	8.00 (+819.44%)
Earnings Date	Apr 15, 2025

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory dis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTB
• Website: https://www.connectbiopharm.com

Analyst Forecast

According to one analyst, the rating for CNTB stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(819.44% upside)

Analyst Consensus: Strong Buy